ArticleClinical drug investigation2025
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation-IL PSO (Italian Landscape Psoriasis).
Abstract readLetter
In one paragraph
Article in Clinical drug investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.Dermatology and therapy · 2026Article
- Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).Journal of clinical medicine · 2026Article
- Effectiveness of Bimekizumab in Multi-Failure Psoriatic Patients: A Retrospective, Real-World Multicenter Study.Journal of personalized medicine · 2026Article
- Real-life effectiveness and safety of bimekizumab in patients with moderate plaque psoriasis: a 54-week multicentre study in the Lazio region.Drugs in context · 2026Article
- Blood-Count-Derived Inflammatory Biomarkers and Characterization of Super-Responder Profile in Psoriatic Patients Receiving Biological Treatment: A Single-Center Study.International journal of molecular sciences · 2025Article
- Super Responders in Plaque Psoriasis: A Real-World, Multi-Agent Analysis Showing Bimekizumab Associated with the Highest Odds of PASI = 0 at Week 12.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Maria Esposito *Department of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy. maria.esposito3@univaq.it.ORCID http://orcid.org/0000-0002-4773-6993
Paolo Gisondi *Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Chiara AssorgiClinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Francesco BellinatoSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Pina BriantiUnit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and Institute for Research and Care, Milan, Italy.
Martina BurlandoSection of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.
Giovanna BrunassoDepartment of Dermatology, Galliera Hospital, Genova, Italy.
Stefano CaccavaleDermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
Giacomo CaldarolaSection of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
Elena CampioneDepartment of Dermatology, University of Rome 'Tor Vergata', Rome, Italy.
Piergiacomo Calzavara PintonDepartment of Dermatology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Anna CampanatiDermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.
Carlo Giovanni CarreraDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Andrea CarugnoDermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
Emanuele CozzaniSection of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.
Antonio CostanzoDermatology Unit, IRCCS Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
Francesco CusanoDepartment of Dermatology, Gaetano Rummo Hospital, Benevento, Italy.
Paolo DapavoDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
Annunziata DattolaDermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
Clara De SimoneSection of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.
Roberta Di CaprioDermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
Federico DiotalleviDermatological Clinic Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.
Maria Concetta FargnoliDepartment of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.
Francesca GaianiDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Alessandro GiuntaDepartment of Dermatology, University of Rome 'Tor Vergata', Rome, Italy.
Piergiorgio MalagoliDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
Angelo Valerio MarzanoDermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Matteo MegnaSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Santo Raffaele MercuriUnit of Dermatology and Cosmetology, Vita-Salute San Raffaele University and Institute for Research and Care, Milan, Italy.
Edoardo MortatoDepartment of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.
Alessandra NarcisiDermatology Unit, IRCCS Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
Diego OrsiniClinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Luca PotestioSection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Pietro QuaglinoDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
Antonio Giovanni RichettaDermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
Francesca RomanoDermatology Unit, AORN "A. Cardarelli", Naples, Italy.
Paolo SenaDermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
Emanuele VagnozziDepartment of Biotechnological ad Applied Clinical Sciences, University of L'Aquila, via Vetoio-Coppito 2, 67100, L'Aquila, Italy.
Marina VenturiniDepartment of Dermatology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Francesco Loconsole *Department of Dermatology, University of Bari, Piazza Umberto I, 1, 70121, Bari, Italy.
Anna Balato *Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.